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In the research for the development of new drugs for the therapy of American tegumentary leishmaniasis, copper has been 
studied for its antileishmania activity. This study aims to report the activity of three copper(I) complexes on parasites of the 
species Leishmania amazonensis and L. guyanensis. The metal complexes were tested according to in vitro antileishmanial 
assays, against promastigote and amastigote forms of the most prevalent species in the state of Amazonas, Brazil. Cytotoxicity 
of the complexes was evaluated in murine macrophage-like cell line (MJ774). The results of the in vitro assays indicated that, 
among the copper complexes tested, the homoleptic phosphine complex [Cu(thp)4][PF6](thp=tris-hydroxymethylphosphine) 
presented promising activity against the evolutionary forms of L. amazonensis, and obtained a IC50 of  26.45 and 24.61 µM in 
a period of 48 and 72 h, respectively. The results for copper complex at concentration 160 µM in amastigote forms showed a 
decrease in the infection index (32% of infected cells) and, in the cytotoxicity assay with MJ774, 52.43% of cell viability was 
observed. The results showed that the complex [Cu(thp)4][PF6] presented significant biological activity, indicating a need for 
future in vivo studies. 
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Resumo  
Na busca do desenvolvimento de novos fármacos para a terapia da leishmaniose tegumentar americana, o cobre tem sido 
estudado quanto a sua atividade antileishmania. Esse estudo tem como objetivo relatar a atividade de três complexos de cobre 
(I) sobre parasitas das espécies Leishmania amazonensis e L. guyanensis. Os complexos metálicos foram testados por meio de 
ensaios antileishmania in vitro contra as formas promastigota e amastigota das espécies mais prevalentes no estado do 
Amazonas, Brasil. A citotoxicidade dos complexos foi avaliada em linhagem de células semelhantes a macrófagos murinos 
(MJ774). Os resultados dos ensaios in vitro indicaram que, entre os complexos de cobre testados, o complexo homoléptico de 
fosfina [Cu(thp)4][PF6](thp=tris-hidroximetilfosfina) apresentou atividade promissora contra as formas evolutivas de L. 
amazonensis, e obtiveram IC50 de 26,45 e 24,61 µM em um período de 48 e 72 h, respectivamente. Os resultados para o 
complexo de cobre na concentração de 160 µM nas formas amastigotas reportaram diminuição no índice de infecção (32% das 
células infectadas) e, no ensaio de citotoxicidade com MJ774, observou-se 52,43% de viabilidade celular. Os resultados 
evidenciaram que o complexo [Cu(thp)4][PF6] apresentou atividade biológica significativa, indicando a necessidade de futuros 
estudos in vivo. 




American cutaneous leishmaniasis (ACL) is a disease 
caused by different species of the genus Leishmania, and is 
classified as cutaneous and mucocutaneous (Blanco & 
Nascimento-Júnior, 2017). ACL is an endemic disease in 92 
countries, and in Brazil it has a high incidence in some of the 
poorer regions (WHO, 2020).  
In 2018, the northern region of Brazil registered 7,519 
cases, followed by the northeastern (3,717 cases), 
midwestern (2,086), southeastern (1,646) and southern (158) 
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regions, with the highest numbers of registered cases in the 
state of Pará (3,081 cases), and Amazonas with 1,684 cases 
(SINAN, 2019). The northern region of Brazil contributes to 
the highest incidence of ACL in Brazil due to the diversity of 
species of Leishmania and sandflies vectors, which is linked to 
the environmental conditions that favor this transmission.  
Currently, meglumine antimoniate, amphotericin B and 
pentamidine isethionate are the standard drugs adopted for the 
treatment of leishmaniasis, however the combination of 
parenteral administration, toxicity and parasitic resistance 
justifies the search for new active principles (Bastos, Boechat, 
Hoelz, & Oliveira, 2016).  
The development of metal complexes aimed at treating 
neglected diseases offers opportunities for pharmaceutical 
products because of their specific and unique physicochemical 
properties (Ong, Roy, Andrews, & Gasser, 2019), variety of 
coordination numbers, different oxidation states 
(Selvaganapathy & Raman, 2016) and the possibility of using 
a multi-target molecule approach for increasing drug efficiency 
(Arndt et al., 2017).  
Arsenic complexes, mercury, bismuth, platinum, antimony, 
gold, iron, gadolinium, samarium, technetium, palladium and 
others are, or have been, used in medicine (Ong et al., 2019). 
However, copper has been the subject of many studies since it 
is an essential metal for most aerobic organisms. It is present 
as a structural and catalytic cofactor of several enzymes (Puig 
& Thiele, 2020) and in several studies, such as that by Gandin 
et al. (2014), it has been shown that copper(I) complexes are 
capable of inhibiting the growth of tumor cells in vitro and in 
vivo. Arndt et al. (2017) and Portas, Miguel, Yokoyama-
Yasunaka, Uliana, and Espósito, (2012) demonstrated that 
different Cu(II) complexes have antileishmanial activity in 
vitro against L. (L.) amazonensis promastigotes.  
According to Tahghighi (2014), the activity of metal 
complexes depends on the metal oxidation state and on the 
nature of the ligands. Thus, considering that the mechanism of 
uptake of copper cells implies a reduction from Cu(II) to Cu(I) 
(Ren et al., 2019), studies such as the one by Saeed et al. (2018) 
have focused mainly on synthesizing Cu(I) complexes as 
potential antileishmanial agents.  
A clear example of the importance of the oxidation state of 
the metal is represented by Navarro et al. (2003a) and Navarro 
et al. (2003b) studies, in which Cu(II) and Cu(I) complexes 
were synthesized using the ligands ppz (dipyride[3,2-a:2',3'-
c]phenazine) and dpq (dipyride[3,2-a:2',3'-h]quinoxoline). The 
compounds showed promising activity, but interestingly the 
Cu(I) [Cu(dppz)2]BF4 derivative was shown to be more active 
in L. (L.) mexicana promastigotes than the corresponding 
Cu(II) derivative [Cu (dppz)2(NO3)](NO3) that was tested on L. 
(V.) braziliensis promastigotes.  
This study aims to report the activity of three copper(I) 
complexes on parasites of the species L. amazonensis and L. 
guyanensis. 
 
Materials and Methods 
 
Copper complexes 
The synthesis of the copper(I) complexes [Cu(thp)4][PF6] 
(thp = tris-hydroxymethylphosphine) (1), [Cu(PTA)4][BF4] 
(PTA = 1,3,5-triaza-7-phosphadamantane) (2) and 
[HB(pz)3Cu(PTA)] (HB(pz)3 = tris(pyrazolyl)borate) (3) 
(Figure 1) was carried out according to the procedures of 
Marzano et al. (2008), Porchia et al.(2009) and Gandin et al. 
(2014). 
    
 
Figure 1. Chemical structures of Cu(I) complexes used in 
this study. 
 
To perform the biological assays, the copper complexes 
were dissolved in dimethyl sulfoxide (DMSO - Vetec®, 4% 
v/v) and Schneider medium, filtered through a membrane 
with 0.22 µm pores, under sterile conditions. In the 
promastigote assay, concentrations ranging from 160 to 10 
µM of the copper complexes were tested using serial 
dilution, and for the cytotoxicity and amastigote assays, a 
160 µM concentration of the copper complex was evaluated. 
For control tests, the standard drug used was pentamidine 
isethionate (Pentacarinat®) (Sanofi Aventis Farmacêutica 
Ltda, Brazil), diluted in Schneider’s insect medium (Sigma-
Aldrich®), and filtered through a syringe filter (Kasvi, 0.22 
µm), under sterile conditions. In the promastigote and 
cytotoxicity assays, ranging concentrations from 9.1 to 147 
µM of the Pentacarinat® were tested by serial dilution means 
and in amastigotes (intracellular form) assays, 147 µM 
concentration of the Pentacarinat® was evaluated. 
 
Origin and maintenance of parasites 
Leishmania (Leishmania) amazonensis 
(MHO/BR/2006/IM5584) and Leishmania (Viannia) 
guyanensis (MHO/BR/95/M4147) were characterized, 
cryopreserved and maintained in the Laboratory of 
Leishmaniasis and Chagas’ Disease, National Institute of 
Amazonian Research – INPA (Manaus, Amazon, Brazil). 
The parasites were cultured in a Novy-MacNeal-Nicolle 
medium (NNN). This culture was expanded in complete 
Schneider’s insect medium (Sigma-Aldrich®), which was 
supplemented with 10% of inactivated fetal calf serum 
(iFCS) and gentamicin 40 µg mL-1 (Novafarma, Brazil). The 
J774 macrophages were kept in culture bottles with complete 
RPMI 1640 medium (Himedia®), supplemented with 20% of 
iFCS, and incubated in an oven at 37 °C. 
 
In vitro promastigote assay 
In 96-well plates promastigote forms (2x106 cells/mL) 
were exposed to different concentrations of copper 
complexes (10 to 160 µM). The control groups consisted of 
promastigotes treated with Pentacarinat® (9.1 to 147 µM) 
and promastigotes without treatment, the DMSO 
concentration ranged from 0.06% to 1% in the plate. The 
biological activity was determined by inhibiting the growth 
3 Acta Brasiliensis 5(1): 1-6, 2021 
Chagas, et al. – Copper (I) complexes against leishmanial 
   
  
of promastigote forms of Leishmania spp. and quantifying 
viable promastigotes in a hemocytometer using an optical 
microscope (Nikon Eclipse E200, Nikon, Japan) at 400x 
magnification, at 24, 48 and 72 hour intervals. Data are 
expressed as a half-maximum inhibitory concentration (IC50) 
and parasitic viability is compared with the controls 
(Comandolli-Wyrepkowski et al., 2017). 
 
In vitro cytotoxicity assay 
The murine macrophage-like cell line J774 (105 cells mL-1) 
were incubated in 96-well plate in a complete Schneider 
medium at 37 °C. After 24 hours of cell adhesion. The cells 
were only exposed to the copper complex (1) that showed the 
best performance in the assay against promastigote forms, and 
the control groups consisted of cells treated with Pentacarinat® 
and cells without treatment, for a period of 24, 48 and 72 hours.  
To determine cell viability, the MTT colorimetric test 
(Roche®) was used, after the incubation periods of 24, 48 and 
72 hours. Subsequently, the optical density (OD) of each well 
plate was evaluated on the spectrophotometer (Bio-TEK®) at 
590 nm. For morphological evaluation, a 24-well plate was 
used, with the same conditions for cultivation and treatment of 
the cells, with subsequent fixation and staining of the 
biological material by the Rapid Panoptic method (Laborclin®, 
Paraná, Brazil). The results were expressed as the percentage 
of viable cells (Comandolli-Wyrepkowski et al., 2017). 
 
In vitro amastigote-macrophage assay 
Macrophages were incubated on a 24-well plate with 105 
cells mL-1 in complete Schneider medium, incubated in an 
oven at 37 °C for 48 hours. Macrophages were then infected 
with 106 cells mL-1 for 2 hours with the L. (L.) amazonensis or 
L. (V.) guyanensis promastigotes. After the infection period, 
the wells were washed with sterile saline solution (NaCl 0.9%) 
for removal of the non-internalized promastigotes. The 
infected macrophages were incubated for 48 hours at 37 °C in 
the presence of copper complex (1) (160 µM) and 
Pentacarinat® (147 µM). After the incubation period, the wells 
were washed with sterile saline solution and the macrophages 
were then fixed and stained using the Quick Panoptic 
(Laborclin®). For the analysis, 100 macrophages were 
quantified (in triplicate) to determine infection rate considering 
infected and uninfected macrophages. Quantification was 
performed using an optical microscope at 1000x magnification 
(Comandolli-Wyrepkowski et al., 2017). 
 
Statistical analysis 
All biological assays were performed in triplicate and the 
results were expressed as average ± standard deviation (SD). 
The data were submitted to one-away analysis of variance and 
p values below 0.05 were considered significant. Tukey's 
multiple comparison test was used to identify significant 
differences in the means among the different treatments 
(GraphPad Prism software, version 6.0). 
 
Results and Discusion 
In the promastigote cells sensitivity test to the three copper 
complexes, both species of Leishmania showed different 
behavior after cultivation in the presence of complexes. 
There was a significant difference between all treatments (p 
< 0.001) in the two species tested. The most promising 
complex against promastigote forms of L. (L.) amazonensis 
was complex (1), which presented an IC50 of 26.45 and 24.61 
µM at 48 and 72 hours, respectively. This IC50 was lower 
than that for Pentacarinat®, however this complex did not 
present a similar activity against L. (V.) guyanensis (Table 
1). 
 
Table 1. Inibitory Concentrations (IC50) of copper complexes 
(1, 2, 3) and Pentacarinat® calculated by linear regression, in 
48 and 72 hour incubation periods with promastigotes of 




48 h 72 h  
[Cu(thp)4][PF6] (1) 26.45 ± 0.24 24.61 ± 0.28 
[Cu(PTA)4][BF4] (2) 89.26 ± 0.79 75.03 ± 0.65 
[HB(pz)3Cu(PTA)] (3) 87.17 ± 0.76 62.11 ± 0.42 
Pentacarinat® 66.28 ± 0.18 27.45 ± 0.61 
 Copper complexes 
L. guyanensis 
48 h 72 h  
[Cu(thp)4][PF6] (1) 105.94 ± 0.01 177.10 ± 0.03 
[Cu(PTA)4][BF4] (2) 330.23 ± 0.05 155.49 ± 0.03 
[HB(pz)3Cu(PTA)] (3) 207.43 ± 0.01 120.36 ± 0.00 
Pentacarinat® 61.55 ± 0.02 58.10 ± 0.00 
 
Considering complex (1) as the most promising, we 
analyzed the statistical difference between the treatments and 
the different concentrations of the complex (1). In L. (L.) 
amazonensis promastigotes, complex (1) showed a 
significant difference to the negative control in 48 hours (p 
= 0.0029) and 72 hours (p = 0.0133), with less parasitic 
viability. There was also a significant difference between the 
complex (1) and Pentacarinat® in the period of 48 hours (p = 
0.0049) and 72 hours (p = 0.0007), with greater parasitic 
viability being observed in the lower concentrations of the 
complex (1) [Figure 2]. 
In promastigote forms of L. (V.) guyanensis, complex (1) 
showed a significant difference, with less minor parasitic 
viability when compared to the negative control in the 48 
hour period (p = 0.0429); complex (1) also showed greater 
parasitic viability compared to Pentacarinat®, with 
significant difference in the period of 48 hours (p = 0.0027) 
and 72 hours (p = 0.0055) [Figure 2]. 
In the cytotoxicity test, the results showed that 52.45% 
(SD 1.29%) of the MJ774 cells were viable after 48 hours of 
incubation with complex (1) at concentration 160 µM. 
Moreover, morphological analysis of the cells exposed to 
complex (1) revealed that in the positive control (untreated 
macrophages) and Pentacarinat® assays (Figure 3A and B, 
respectively), the MJ774 cells did not present any 
morphological alterations, whereas when using treatment 
with complex (1) the presence of vacuoles in the cytoplasm 
was notable (Figure 3C). 
Thus, the effectiveness of complex (1) was tested against 
the amastigote forms of L. (L.) amazonensis and L. (V.) 
guyanensis internalized in MJ774 cells. The results showed 
that the rate of infection of L. (L.) amazonensis was 32% (SD 
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1.4%) when macrophages were treated with a 160 µM 
concentration of complex (1), and 19% (SD 0.90%) when 




Figure 2. Antileishmanial activity of the copper complex 
(1) in promastigote forms of Leishmania (Leishmania) 
amazonensis (A) and L. (Viannia) guyanensis (B). Legend: 
NC: Negative control; P: Pentacarinat® (147 µM). Means followed 
by the same lowercase (for 48h interval) and uppercase (for 72h) 
letters, in each graphic, do not differ from each other by the Tukey 




Figure 3. In vitro cytotoxicity morphological assay with 
MJ774 cells after 48 hours of incubation. A: Positive control 
(untreated macrophages), B: macrophages treated with 
Pentacarinat® C) macrophages treated with 160 µM of copper 
complex (1). 1000 x magnification.  This figure is in color in 
the electronic version.  
 
The morphological analysis of the cells exposed to the in 
vitro amastigote-macrophage assay revealed that the infected 
and untreated macrophages showed internalized amastigotes 
with the presence of small vacuoles, and the same was 
observed in infected macrophages and those treated with 
Pentacarinat®. When the infected macrophages were treated 
with complex (1), the presence of amastigotes interiorized in 
vacuoles was observed, in addition to the intense vacuolization 
of the macrophages (Figure 4).  
When the macrophages were infected with L. (V.) 
guyanensis and treated with a 160 µM concentration of 
complex (1), there was a total lysis of the macrophages, and 
was considered a 100% infection, therefore it was not possible 
to perform morphological records due to cellular 
degradation. 
In a research conducted by Portas et al. (2012), using 
copper(II) complexes, also observed antileishmanial activity 
against promastigote forms of L. (L.) amazonensis. The 
results showed that the acetylacetonate (acac) derivative, 
namely Cu(acac)2, showed the best activity at 24 hours with 
an IC50 of 31 µM, but demonstrated an increase during the 
incubation period (IC50 of 94 µM at 72 hours), whereas the 
more lipophilic fluoroderivative Cu(tfacac)2 increased its 
activity during the incubation period (IC50 of 68 and 43.0 µM 
at 24 and 72 hours respectively).  
 
 
Figure 4. In vitro amastigote - macrophage assay with 
Leishmania (Leishmania) amazonensis.  A) Positive control 
(non-infected and untreated macrophages, B) infected and 
untreated macrophages, C) infected macrophages and treated 
with Pentacarinat® and D) infected macrophages and treated 
with 160 µM of copper complex (1). 1000x magnification. 
This figure is in color in the electronic version. 
 
The key factors for the efficacy of the Cu(II) complexes 
tested  by Portas et al. (2012) are the high lipophilicity and 
the pro-oxidant activity, as lipophilic complexes are better 
inhibitors of trypanothione reductase (TR). In our case, we 
used water-soluble, or highly hydrophilic, Cu(I) compounds 
that presented a lower or a similar IC50 compared to those 
reported in the literature, suggesting a different mechanism 
of action.   
In particular, complex (1) demonstrated itself to be the 
most promising against the promastigote forms of L. (L.) 
amazonensis when compared to the other two complexes 
tested, presenting an IC50 value lower than the values 
reported in previous studies (IC50 of 26.45 and 24.61 µM at 
48 and 72 hours). Regarding the activity of the copper(I) 
complex against L. (V.) guyanensis, there was a decline in 
the IC50, suggesting a long-term activity. However, no other 
study was found that used copper complexes against L. (V.) 
guyanensis. 
Complex (2) is a homoleptic compound comprising the 
metal tetrahedrally arranged in a cationic moiety, which 
differs from complex (1) due to the nature of the phosphine 
(PTA instead of thp). This difference demonstrated a 
noticeable decrease in the activity against L. (L.) 
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at 48 and 72 hours respectively, which is about three times 
higher than those obtained with complex (1). As observed for 
complex (1), complex (2) was also even less active against L. 
(V.) guyanensis, showing significant increase in IC50 during the 
incubation period (IC50 of 330.23 and 155.49 µM
 at 48 and 72 
hours, respectively).  
Compound (3) is a lipophilic neutral mixed-ligand 
(scorpionate/phosphane) species, and its mechanism of 
internalization and of action might be different from those of 
complexes (1) and (2). In fact, complexes (1) and (2) in diluted 
solutions, such as those utilized for biological tests, are 
partially dissociated and the predominant species in the 
solution are the coordinatively unsaturated CuP2
+/CuP3
+ 
species. These can be internalized in the cell by an active 
transport mechanism using Ctr1 transporters, whereas 
compound (3), even at low concentrations, does not lose 
ligands and remains as a neutral lipophilic entity that can be 
internalized by a passive diffusion transport mechanism 
(Gandin et al., 2014; Tisato et al., 2016; Quaretti et al., 2018). 
In fact, as it appears from the IC50 values, the activity of (3) 
is similar, or slightly better, than the activity of (2), suggesting 
that lipophilicity is not the key factor. However, as in the study 
by Portas et al. (2012), compound (3) showed lipophilicity and 
obtained a decrease in IC50 during the incubation period, 
suggesting long-term activity.  
In the literature, the activity of a cationic drug, such as 
paromomicyn, can be related to its ability to bind to the 
negatively-charged leishmanial glycoprotein−polysaccharide 
layer covering the cell membrane (Jhingran, Chawla, Saxena, 
Barrett, & Madhubala, 2009). In our case, both complexes (1) 
and (2) are positively charged, so the charge is not a key factor 
for explaining the remarkable activity of (1). Among the three 
complexes tested, (1) is the most active compound against both 
evolutionary forms of the life cycle of L. (L.) amazonensis.  
Further studies are needed to elucidate the mechanism(s) of 
action of the compounds tested in this study, in particular their 
ability to inhibit TR, since this is an enzyme which is exclusive 
to organisms that belong to the Trypanosomatidae family, this 
made it a potential chemotherapeutic target. In addition, it was 
found that antimony compounds have the ability to inhibit TR, 
which may be one of the mechanisms of action for the current 
treatment of leishmaniasis (Tunes et al., 2020). Studies, such 
as the one by Tunes et al. (2020), have sought to investigate the 
ability of gold complexes to inhibit TR and it was found that 
gold complexes were active against Leishmania spp. (IC50 of 
0.5 to 5.5 µM) and all gold(I) complexes were potent inhibitors 
of TR, which demonstrates that although antileishmanial 
activity may involve several mechanisms, one strategy is to 
ascertain the potential for inhibiting TR. 
In relation to cytotoxicity, Singh et al. (2017) performed 
biological cytotoxicity assays on macrophages of mammalian 
hosts and the results revealed that copper salisylaldoxime (30 
µM and 45 µM) is almost non-toxic to host cells. In our study, 
we observed intense vacuolization in macrophages treated with 
complex (1). This fact may be associated with the mechanisms 
described by Tisato et al. (2016), who suggested that complex 
(1) does not induce cell apoptosis or DNA fragmentation, but 
it does induce cell paraptosis through the stress of the 
endoplasmic reticulum in cancer cells, causing their death. 
In experimental studies with intracellular forms, Britta et 
al. (2012) evaluated the activity of a copper complex against 
L. (L.) amazonensis and the infectivity rate was 62.3% to 
14.4%. The results presented for Britta et al. (2012) are 
similar to those of this study since the infectivity rate was 
32%.  
A relevant factor in assays with amastigote forms was the 
intense vacuolization of macrophages exposed to complex 
(1), which maybe associated with an increase in infection. 
Young and Kima (2019) recently showed that L. (L.) 
amazonensis infections are more successful when autophagy 
increases in host cells, in addition to an increase in parasitic 
load in BALB/c macrophages. 
 
Conclusion 
The phosphine copper(I) complex [Cu(thp)4][PF6] (thp = 
tris-hydroxymethylphosphine) (1) presented promising 
activity against both evolutionary forms in the  life cycle of 
L. (L.) amazonensis and showed moderate toxicity in murine 
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